Panitumumab: 10 años y avanzando en el tratamiento del CCRm RAS WT

33 / 40

Mantenimiento
1. CRC treatment continuum representation based on: Van Cutsem E, et al. Ann Oncol 2016;27:1386‒422; 2. ClinicalTrials.gov identifier: NCT01991873 (accessed 08-03-
18); 3. ClinicalTrials.gov identifier: NCT01384994 (accessed 08-03-18); 4. ClinicalTrials.gov identifier: NCT02476045 (accessed 08-03-18); 5. Nakamura M et al. GICS 2018.
Abstract 729 & poster
Valentino: NCT024760454 SAPPHIRE5
PanaMa: NCT019918732
mCRC
WT RAS
(N ~ 380)
Panitumumab
6 mg/kg Q2W
+ mFOLFOX6 Q2W
CR/PR
or SD at
12 weeks
R
5-FU/FA† Q2W
Panitumumab
6 mg/kg Q2W
+ 5-FU/FA† Q2W Panitumumab6 mg/kg Q2W
+ mFOLFOX6
Q2W
Induction Maintenance Re-induction
on progression
Panitumumab
6 mg/kg Q2W
+ FOLFOX4
Q2W
R
Induction Maintenance
1st-line
mCRC
WT RAS
(N ~ 224)
Advanced/
recurrent CRC
WT RAS†
(N ~ 164)
Panitumumab
6 mg/kg +
+ mFOLFOX6 Q2W
x 6 cycles
CR/PR
or SD R
Panitumumab
6 mg/kg +
5-FU/LV Q2W
Panitumumab
6 mg/kg +
mFOLFOX6Q2W
Induction Maintenance
Panitumumab
6 mg/kg Q2W
+ 5-FU/LV Q2W
Panitumumab
6 mg/kg Q2W
Panitumumab
6 mg/kg Q2W
+ FOLFOX4
Q2W
Disease progression/unacceptabletoxicity/consent withdrawal
Treatment up to 8 cycles